Truncating SLC5A7 mutations underlie a spectrum of dominant hereditary motor neuropathies
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 27, 2017
- Accepted in final form November 15, 2017
- First Published March 23, 2018.
Author Disclosures
- Claire G. Salter, BMBS*,
- Danique Beijer, MSc*,
- Holly Hardy, PhD,
- Katy E.S. Barwick, PhD,
- Matthew Bower, MS,
- Ines Mademan, PhD,
- Peter De Jonghe, PhD,
- Tine Deconinck, MSc,
- Mark A. Russell, PhD,
- Meriel M. McEntagart, BMBS, MD,
- Barry A. Chioza, PhD,
- Randy D. Blakely, PhD,
- John K. Chilton, PhD,
- Jan De Bleecker, PhD,
- Jonathan Baets, PhD,
- Emma L. Baple, PhD,
- David Walk, MD and
- Andrew H. Crosby, PhD
- Claire G. Salter, BMBS*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Danique Beijer, MSc*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Holly Hardy, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katy E.S. Barwick, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew Bower, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ines Mademan, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter De Jonghe, PhD,
NONE
NONE
NONE
(1) Acta Neurologica Belgica; editorial advisory board; 2009-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tine Deconinck, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark A. Russell, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Foundation for the Study of Diabetes (EFSD) 2015 ?50000
NONE
NONE
NONE
NONE
NONE
NONE
- Meriel M. McEntagart, BMBS, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Barry A. Chioza, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Randy D. Blakely, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
5 R01 MH094527 (Blakely, PI) 08/01/17-06/30/22 NIH/NIMH Regulation of Serotonin Transporters: This project explores the ability of inflammatory cytokine and p38 MAPK signaling to impose a biased conformation on the serotonin transporter (SERT), modulating transporter activity state, and mimicking the functional impact of autism-associated SERT mutations. 5 R01 MH105094 (Blakely, PI) 09/01/14-08/31/19 NIH/NIMH Knock-In Mouse Model of Dopamine Dysfunction Underlying Traits of ADHD: This project explores the biochemical, physiological and behavioral perturbations in the DAT Val559 mouse model of ADHD.
NONE
SFARI Award, Simons Foundation (Blakely, PI) 09/01/14-08/31/17 Immune p38 MAPK Activation: Convergent Mechanism Linking ASD Models: This project examines p38 MAPK as a mechanism by which maternal immune activation in a mouse model produces features of autism and whether these features show similarities to genetic insults.
NONE
1) Molecular Devices
1) Fluorescent neurotransmitter substrates, MolecularDevices, 20116-2017
NONE
NONE
NONE
- John K. Chilton, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Northcott Devon Medical Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Jan De Bleecker, PhD,
(1) Sanofi/Genzyme; (2) Pfizer
NONE
Sanofi/Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan Baets, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emma L. Baple, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Walk, MD and
Pfizer, advisory board, 2009 AstraZenica, advisory board, 2009 Neurogesx, advisory board, 2010 Acceleron, advisory board, 2016
NONE
1. Acceleron Pharma,consulting fee
Pain Medicine, Associate Editor
NONE
NONE
NONE
NONE
Eli Lilly, 2008, 2009
NONE
I perform clinical consultations and electrodiagnostic studies, 50% time, for the University of Minnesota
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew H. Crosby, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Medical Research Council, REF: G1002279, PI, 2012-2015.
NONE
(1) Newlife Foundation, REF: 16-17/12 (2) Neurosciences Research Foundation, REF: 12583-10 (3) Spastic Paraplegia Support Group/ Diamond Jubilee Fund, REF: T620022370.
NONE
NONE
NONE
NONE
NONE
NONE
- From the RILD Wellcome Wolfson Centre (C.G.S., H.H., K.E.S.B., M.A.R., B.A.C., J.K.C., E.L.B., A.H.C.), Royal Devon & Exeter NHS Foundation Trust, Exeter; Wessex Clinical Genetics Service (C.G.S.), Princess Anne Hospital, Southampton, United Kingdom; Neurogenetics Group (D.B., I.M., P.D.J., T.D., J.B.), Center for Molecular Neurology, VIB; Laboratory of Neuromuscular Pathology (D.B., I.M., P.D.J., T.D., J.B.), Institute Born-Bunge, University of Antwerp; Department of Neurology (M.B., D.W.), University of Minnesota, Minneapolis, MN; Department of Neurology (P.D.J., J.B.), Neuromuscular Reference Centre, Antwerp University Hospital, Antwerpen, Belgium; Clinical Genetics (M.M.M.), St. George's University of London, London, United Kingdom; Biomedical Science (R.D.B.), Florida Atlantic University, Jupiter Campus, FL; and Department of Neurology (J.D.B.), University Hospital Ghent, Ghent, Belgium; Peninsula Clinical Genetics Service (E.L.B.), Royal Devon and Exeter Hospital, Exeter, United Kingdom.
- Correspondence
Prof. Crosby A.H.Crosby{at}exeter.ac.uk or Dr. Walk walkx001{at}umn.edu
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.